Skip to main content

Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study With Sabarish Ayyappan, MD

Oncology Data Advisor® · Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study: Sabarish Ayyappan, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Sabarish Ayyappan, MD, the Director of Hematological Malignancies at the City of Hope Cancer Center, to discuss the ELM-2 study which investigated odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).   Oncology...

Continue reading

Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL With Jon Arnason, MD

Oncology Data Advisor® · Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL: Jon Arnason, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Jon Arnason, MD, a Lymphoma Clinical Trial Specialist at Beth Israel Deaconess Medical Center, to discuss his abstract and presentation regarding the ELM-2 trial which studied circulating tumor DNA (ctDNA) as a predictive biomarker with odronextamab for follicular lymphoma (F...

Continue reading

Maintaining Functioning and Quality of Life With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD

Oncology Data Advisor® · Maintaining Functioning and QOL With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Benoit Tessoulin, MD, PhD, Head of the Lymphoma Department at the Nantes University Hospital in France, sat down with Oncology Data Advisor to discuss the results from the ELM-2 study in which the efficacy of odronextamab was investigated for maintaining functionality and quality of life in patients ...

Continue reading